We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


TriPath Imaging Announces Receipt of BD Proposal

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

TriPath Imaging, Inc. has announced that it has received a proposal from BD (Becton, Dickinson and Company) acquire the approximately 93.5% of the outstanding shares of TriPath Imaging, Inc. that BD does not currently own.

The proposal provides that each share of TriPath Imaging would be exchanged for $9.25 in cash pursuant to the terms of a merger agreement to be negotiated by the parties.

The proposal arose after a review by TriPath Imaging of potential strategic opportunities.

TriPath Imaging, through its TriPath Oncology business unit, has worked closely with BD since July 2001 to develop and commercialize molecular diagnostic products for melanoma and cancer of the cervix, breast, ovary and prostate.

TriPath Imaging's Board of Directors will thoroughly evaluate the offer with the assistance of its financial advisors, UBS Securities LLC.

BD currently holds approximately 6.5% of TriPath Imaging's outstanding stock, and therefore was required to make a public filing under Section 13 of the Securities and Exchange Act of 1934 upon making a proposal to acquire TriPath Imaging.

This announcement is made to confirm that filing by BD. Since TriPath Imaging and BD have not entered into a definitive agreement, further discussion of the proposal would be premature at this time.